

LATAM Pain Management Drugs Market Value\$3,383.20 Million, Globally, by 2027 at 3.5% CAGR

The increase in the number of surgical procedures and the increase in healthcare costs are expected to increase the market for LATAM pain management drugs.

PORTLAND, OREGON, US, July 15, 2022 /EINPresswire.com/ -- According to a new report published by Allied Market Research, titled, the <u>LATAM Pain</u> Management Drugs Market was valued at \$2,683.82 million in 2019, and is projected to reach \$3,383.20 million by 2027, registering a CAGR of 3.5% from



LATAM Pain Management Drugs Market

2020 to 2027. Growth in the geriatric population is a key factor driving the growth of the LATAM pain management market, as older people are more likely to suffer from joint pain and other chronic conditions. Furthermore, the growth of the market in Latin America is fueled by the rise in chronic diseases such as cancer, diabetic nephropathy, and osteoarthritis.

Explore More Insights@ https://www.alliedmarketresearch.com/request-sample/7953

The increase in the number of surgical procedures and the increase in healthcare costs are expected to increase the market for LATAM pain management drugs. However, the exploitation of prescriptions, the patent expiration of prescription pain medications, and the availability of alternatives such as painkillers have hindered the growth of the Latin American market. Pain is a disturbing sensation and emotional sensation, caused by tissue injury or disease. Furthermore, various disorders can cause discomfort, such as multiple sclerosis, osteoarthritis, stomach ulcers, acute arthritis, fibromyalgia, diabetic neuropathy, and cancer.

The LATAM pain management drugs market is segmented on the basis of drug class, indication and region. On the basis of drug class, the market is segmented into nonsteroidal anti-inflammatory drugs (NSAIDs), anaesthetics, anticonvulsants, antimigraine agents, antidepressants, opioids, and non-narcotic analgesics.

Key Market Players

- Abbott Laboratories
- Axon Pharma
- •Bli Lily And Company
- Grünenthal
- •Glaxosmithkline Plc (Gsk)
- Dhnson & Johnson
- •Merck & Co., Inc.
- •Mylan N.V.
- •Novartis International Ag
- •Bfizer Inc.
- •Banofi

Speak With Analyst@ https://www.alliedmarketresearch.com/connect-to-analyst/7953

The duration of pain ranges from short-term acute pain to chronic pain. Acute pain is pain that starts suddenly while chronic pain is caused by bone and joint enlargement, nerve damage or injury. Pain management involves reducing or treating pain using a given class of medications. There are many medications available that reduce pain through various physiological mechanisms such as targeted interceptors.

Key Advantages:

- •In-depth analysis of the LATAM pain management drug market along with the current trends and future estimations to elucidate the imminent investment pockets.
- •A comprehensive analysis of the factors that drive and restrict the market growth is provided in the report.
- The LATAM pain management drugs market forecast is studied from 2020 to 2027
- •Domprehensive quantitative analysis of the industry from 2019 to 2027 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.
- •Extensive analysis of the key segments of the industry helps to understand the application and products of pain management used across the globe.
- Key market players and their strategies have been analysed to understand the competitive outlook of the LATAM pain management drugs market.

Brazil accounted for majority of the LATAM pain management drugs market share in 2019, and is expected to remain dominant throughout the forecast period. This was attributed to large number of aging population and favorable regulatory conditions. Rise in number of drug abuse cases and addictive nature of opioids has decreased use of prescriptions for opioids in the region, leading to decline in opioid consumption for pain management. On the other hand, Argentina is expected to experience highest growth rate during the forecast period, mainly attributable to presence of larger patient pool and increase in healthcare expenditure in the region.

Customization Request@ https://www.alliedmarketresearch.com/request-for-customization/7953

Related Report:

Ophthalmic OR Microscopes Market Cannabis Testing Market

We also Offers Regional and Country Reports:

- •North America Pain Management Drugs Market
- •Japan Pain Management Drugs Market
- •Bouth Korea Pain Management Drugs Market
- •Bingapore Pain Management Drugs Market
- Australia Pain Management Drugs Market
- •Burope Pain Management Drugs Market

About Us:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP, based in Portland, Oregon. AMR provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

AMR introduces its online premium subscription-based library Avenue, designed specifically to offer cost-effective, one-stop solution for enterprises, investors, and universities. With Avenue, subscribers can avail an entire repository of reports on more than 2,000 niche industries and more than 12,000 company profiles. Moreover, users can get an online access to quantitative and qualitative data in PDF and Excel formats along with analyst support, customization, and updated versions of reports.

David Correa
Allied Analytics LLP
800-792-5285
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2022 Newsmatics Inc. All Right Reserved.